AI-generated analysis. Always verify with the original filing.
Biomea Fusion, Inc. reported financial results for the full year ended December 31, 2025, with a net loss attributable to common stockholders of $61.8 million and cash, cash equivalents, and restricted cash of $56.2 million, projecting a cash runway into the first quarter of 2027. The company highlighted clinical progress including 52-week data from COVALENT-111 and initiations of COVALENT-211, COVALENT-212, and GLP-131 trials.
Event Type
Disclosure
Mandatory
Variant
8-K
of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
Financial Statements and Exhibits. (d) Exhibits. 99.1 Press release dated March 24, 2026, furnished herewith. 104 Cover Page Interactive Data File (embedded wit
| Metric | Value | Basis |
|---|---|---|
| Net Loss Attributable to Common Stockholders | $-61.80 | GAAP |
| Loss from Operations | $-83.51 | GAAP |
| Research and Development Expenses | $62.00 | GAAP |
| General and Administrative Expenses | $19.30 | GAAP |
| Net Loss per Common Share, Basic and Diluted | $-1.18 | GAAP |